Lucid Diagnostics Inc.
LUCD Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 23, 2026
$0.41
KIRA · Stoqly’s AI analyst, in plain words
- Lucid Diagnostics Inc. had $4.7M of revenue in fiscal 2025, up 8.3% on the year before.
- Its operating margin was −1,054.8%, up 4.8 pts: of every 100 in sales, about −1,055 is left after running the business.
- Lucid Diagnostics Inc. lost $58.0M in fiscal 2025.
- Free cash flow was −$46.7M in fiscal 2025, −992.0% of revenue.
Market cap
—
P/E
—
Revenue
$4.7M
Net income
−$58.0M
Free cash flow
−$46.7M
Operating margin
−1,054.8%
Lucid Diagnostics Inc. in 30 seconds · fiscal 2025
Are sales growing?
+8.3%
Yes. Sales grew 8.3% last year.
Does it make a profit?
−1,232.7%
No. It lost money last year.
Does profit turn into cash?
−992.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
What Lucid Diagnostics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 25, 2026
- Legal name
- Lucid Diagnostics Inc.
- CIK
- 0001799011
Lucid Diagnostics Inc. · LUCD
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.5M | $0.4M | $2.4M | $4.3M | $4.7M |
| Revenue growth | — | −24.6% | 544.0% | 79.0% | 8.3% |
| Gross margin | 100.0% | 100.0% | — | −63.3% | −41.7% |
| Operating margin | −5,483.8% | −14,920.7% | −1,996.8% | −1,059.6% | −1,054.8% |
| Net income | −$28.1M | −$56.2M | −$52.7M | −$45.5M | −$58.0M |
| Net margin | −5,615.6% | −14,899.5% | −2,169.1% | −1,047.6% | −1,232.7% |
| Diluted EPS | −$1.51 | −$1.55 | −$1.26 | −$1.05 | — |
| Cash | |||||
| Cash from operations | −$17.7M | −$29.7M | −$32.8M | −$44.1M | −$46.5M |
| Capital expenditure | $0.9M | $3.2M | — | $0.3M | $0.2M |
| Free cash flow | −$18.5M | −$32.9M | — | −$44.4M | −$46.7M |
| FCF margin | −3,706.0% | −8,722.8% | — | −1,022.5% | −992.0% |
| Share count change | 31.8% | 94.4% | 15.4% | 21.0% | — |
| Debt and strength | |||||
| Cash and short-term investments | $53.7M | $22.5M | $18.9M | $22.4M | $34.7M |
| Shareholders' equity | $54.7M | $23.0M | −$2.3M | $5.4M | $10.9M |
| Current ratio | 13.5x | 2.9x | 0.8x | 1.1x | 1.3x |
| Interest coverage | −41.6x | −7,031.4x | −116.5x | −1,771.2x | −2,256.4x |
| Returns and quality | |||||
| Return on equity | −136.2% | −144.4% | −508.0% | −2,956.4% | −710.6% |
| Return on tangible equity | −51.3% | −286.6% | — | −1,139.1% | −664.4% |
| Piotroski F-score | — | 2 | 2 | 4 | 4 |
| Altman Z'' | 14.0 | −15.7 | −31.8 | −31.1 | −28.5 |
Insiders bought, 12 months
$0.2M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Lucid Diagnostics Inc. · LUCD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.41 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001799011). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.